IRF8 and lymphomagenesis
IRF8 和淋巴瘤发生
基本信息
- 批准号:9898227
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-04-01 至 2021-03-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdultAffectAgreementAnimal ModelApoptosisB Cell ProliferationB cell differentiationB lymphoid malignancyB-Cell DevelopmentB-Cell LymphomasB-LymphocytesBCL2 geneBCL6 geneBalkansBiologicalBiologyBiopsyBlood CellsCD19 geneCell LineChemical ExposureChromosomal translocationClinicalComplexDNADataDeletion MutationDevelopmentDiagnosisDiseaseEarly DiagnosisEctopic ExpressionEmu speciesEnhancersEnzymesEpigenetic ProcessFamilyFosteringFunctional disorderGene FusionGenesGeneticGenetic TranscriptionGenomicsGoalsHumanIFN consensus sequence binding proteinIGH@ gene clusterImmuneImmuno-ChemotherapyImmunoglobulin Somatic HypermutationIn VitroIncidenceInfectious AgentInterferonsKnowledgeLesionLinkLymphomaLymphomagenesisMLL2 geneMaintenanceMalignant - descriptorMalignant NeoplasmsMalignant lymphoid neoplasmMapsMassive Parallel SequencingMature B-LymphocyteMilitary PersonnelModelingMusMutateMutationOncogenesOncogenicOther GeneticsPAX5 genePRDM1 genePathogenesisPathway interactionsPatientsPhenotypePhysiologicalPoint MutationPopulationProcessProteinsReactionReportingResearchResistanceRiskRoleSecondary toSomatic MutationStructure of germinal center of lymph nodeTestingTherapeuticTransgenic OrganismsTumor Suppressor GenesTumor Suppressor ProteinsVariantVeteransVietnamWestern Worldactivation-induced cytidine deaminasecancer typegain of functionhistone methyltransferasein vivolarge cell Diffuse non-Hodgkin&aposs lymphomamembermouse modelmutantnext generation sequencingnovelnovel markerplasma cell differentiationpressureprogramstraittranscription factortumor
项目摘要
The advent of massive parallel sequencing highlighted the genetic complexity of cancer, and unveiled the
putative contribution of several unsuspected genes to the process of malignant transformation. These
advances also indicated a need for the systematic examination of newly-found mutant genes as to determine
whether they truly contribute to cancer pathogenesis, or simply represent innocuous variants irrelevant to the
observed phenotype. Diffuse large B cell lymphoma (DLBCL), the most common lymphoid malignancy in
adults, is curable in only ~60% of cases. This clinical challenge is associated with the disease’s complex
genetics, which include disruption of epigenetic modifiers, constitutive activation of the NF-κB pathway, and
deregulation of B cell relevant transcription factors. The latter, can derive from chromosomal translocation,
genomic amplification/deletions and somatic mutations. Recently, we developed an IGH-targeted
capture/sequencing strategy and discovered novel aberrant gene fusions in DLBCL including the juxtaposing
of IRF8 (interferon regulatory factor 8) to the IGH locus, t(14;16)(q32;q24), a prototypical model of transcription
factor deregulation in B cell lymphomas. Independently, IRF8 was found to be somatically mutated in ~10% of
DLBCL biopsies. Interestingly, close to 50% of the IRF8-mutant DLBCLs also have mutations in KMT2D, a
histone methyltransferase that when inactivated enhances the lymphomagenic potential of other genetic
lesions. IRF8, a member of the interferon family of transcription factors, is expressed in the germinal center
(GC) where it directly influences the expression of several key regulators of the GC reaction, including BCL6,
AICDA and PRDM1. The central objective of this proposal is to test the hypothesis that IRF8 is a bona fide
oncogene in DLBCL, which can be deregulated by chromosomal translocation and somatic mutations. To
advance this concept, we found that ectopic expression of IRF8 in DLBCL cell lines promotes a
lymphomagenic profile characterized by induction of BCL6 and AICDA, suppression of PRDM1 and resistance
to apoptosis. In addition, we generated preliminary data to show that the missense IRF8 mutants found in
DLBCL are all gain-of-function. Lastly, we created a mouse with B cell restricted transgenic expression of Irf8.
Building on our preliminary data, and on the availability of this novel animal model, we propose to address the
following specific aims: 1) Determine the mechanism for Irf8 lymphomagenesis in a mouse model that mimics
the IGH/IRF8 fusion found in human DLBCL; 2) Characterize in vivo the pro-lymphoma cooperation between
the oncogenic Irf8 and the tumor suppressor Kmt2d; 3) Define the functional consequences of the somatic
IRF8 mutations found in DLBCL. When this project is completed, we will show that IRF8 functions as an
oncogene that cooperates with KMT2D loss for the development of DLBCL. We also expect to mechanistically
link IRF8’s lymphomagenesis to the deregulation of BCL6, AICDA and PRDM1.
大规模平行测序的出现突出了癌症的遗传复杂性,并揭示了癌症的遗传复杂性。
几个未被怀疑的基因对恶性转化过程的假定贡献。这些
这些进展也表明,需要对新发现的突变基因进行系统的检查,以确定
它们是否真的有助于癌症发病机制,或者仅仅代表与癌症无关的无害变体。
观察到的表型。弥漫性大B细胞淋巴瘤(DLBCL)是美国最常见的淋巴系统恶性肿瘤,
成年人,只有约60%的病例可以治愈。这种临床挑战与疾病的复杂性有关,
遗传学,包括表观遗传修饰剂的破坏,NF-κ B途径的组成性激活,以及
B细胞相关转录因子的失调。后者可能来自染色体易位,
基因组扩增/缺失和体细胞突变。最近,我们开发了一种IGH靶向
捕获/测序策略,并在DLBCL中发现了新的异常基因融合,
IRF8(干扰素调节因子8)的IGH基因座,t(14; 16)(q32; q24),转录的原型模型
B细胞淋巴瘤中因子失调。独立地,发现IRF8在约10%的人中发生体细胞突变。
DLBCL活检。有趣的是,接近50%的IRF8突变DLBCL也具有KMT2D突变,
组蛋白甲基转移酶,当失活时,可增强其他遗传因子的淋巴瘤发生潜力,
病变IRF8是干扰素家族转录因子的一员,在生发中心表达
(GC)其中它直接影响GC反应的几个关键调节因子的表达,包括BCL 6,
AICDA和PRDM1。本提案的中心目标是检验IRF8是善意的假设。
DLBCL中的癌基因,其可通过染色体易位和体细胞突变而失调。到
提出这一概念后,我们发现IRF8在DLBCL细胞系中的异位表达促进了DLBCL细胞的增殖。
以BCL 6和AICDA诱导、PRDM 1抑制和耐药性为特征的淋巴瘤发生谱
到凋亡。此外,我们产生的初步数据表明,在大肠杆菌中发现的IRF8错义突变体,
DLBCL都是功能获得性的。最后,我们创建了一只具有B细胞限制性Irf 8转基因表达的小鼠。
基于我们的初步数据,以及这种新型动物模型的可用性,我们建议解决
1)确定在小鼠模型中Irf8淋巴瘤发生的机制,
在人DLBCL中发现的IGH/IRF8融合; 2)在体内表征人DLBCL与IGH/IRF8之间的促淋巴瘤协同作用。
致癌的Irf8和肿瘤抑制因子Kmt2d; 3)定义体细胞的功能后果,
在DLBCL中发现IRF8突变。当这个项目完成后,我们将展示IRF8的功能,
在DLBCL的发展中与KMT2D缺失协同作用的癌基因。我们还希望机械地
将IRF8的淋巴瘤发生与BCL 6、AICDA和PRDM 1的失调联系起来。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ricardo C Aguiar其他文献
Ricardo C Aguiar的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ricardo C Aguiar', 18)}}的其他基金
Mitochondrial 2-hydroxyglutarate dehydrogenases modulate the cellular epitranscriptome
线粒体 2-羟基戊二酸脱氢酶调节细胞表观转录组
- 批准号:
10322194 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Mitochondrial 2-hydroxyglutarate dehydrogenases modulate the cellular epitranscriptome
线粒体 2-羟基戊二酸脱氢酶调节细胞表观转录组
- 批准号:
10117575 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Mitochondrial 2-hydroxyglutarate dehydrogenases modulate the cellular epitranscriptome
线粒体 2-羟基戊二酸脱氢酶调节细胞表观转录组
- 批准号:
10541234 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Post-Translational Control of TET Function in Lymphoma
淋巴瘤 TET 功能的翻译后控制
- 批准号:
10251482 - 财政年份:2013
- 资助金额:
-- - 项目类别:
Post-Translational Control of TET Function in Lymphoma
淋巴瘤 TET 功能的翻译后控制
- 批准号:
10512054 - 财政年份:2013
- 资助金额:
-- - 项目类别:
Non-coding RNAs at the interface of aberrant NF-kB signals and lymphomagenesis
异常 NF-kB 信号与淋巴瘤发生界面的非编码 RNA
- 批准号:
8974297 - 财政年份:2013
- 资助金额:
-- - 项目类别:
Non-coding RNAs at the interface of aberrant NF-kB signals and lymphomagenesis
异常 NF-kB 信号与淋巴瘤发生界面的非编码 RNA
- 批准号:
8436704 - 财政年份:2013
- 资助金额:
-- - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
- 批准号:
10065645 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)